Biomea Fusion Q2 net loss $8.3M, cash $35.2M; T1D C-peptide data positive

Biomea Fusion, Inc.

2026-Q2 EPS reported -$0.29

Net loss of $8.3M for Q2 2026, down from $20.7M in Q2 2025; cash $35.2M as of June 30, 2026.
Cash runway projected into Q2 2027.
Phase II COVALENT-211 (T2D insulin-deficient) data expected Q1 2027; COVALENT-212 (T2D on GLP-1 RA) data expected Q2 2027.
Phase I GLP-131 (BMF-650 obesity) initial 28-day weight reduction data expected Q3 2026.
T1D data: 52% increase in mean C-peptide AUC at Week 12 with icovamenib 200 mg; planning Phase II trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.